{"id":390922,"date":"2017-08-25T00:00:00","date_gmt":"2017-08-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/bioeon0001-biopharma-biosimilars-emerging-biosimilars-truxima-launch-tracker-germany-wave-1-2017\/"},"modified":"2026-03-31T10:50:01","modified_gmt":"2026-03-31T10:50:01","slug":"bioeon0001-biopharma-biosimilars-emerging-biosimilars-truxima-launch-tracker-germany-wave-1-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/bioeon0001-biopharma-biosimilars-emerging-biosimilars-truxima-launch-tracker-germany-wave-1-2017\/","title":{"rendered":"Biosimilars | Emerging Biosimilars | Truxima Launch Tracker | Germany | Wave 1 | 2017"},"content":{"rendered":"<p>In April 2017, Truxima (rituximab), Celltrion\u2019s biosimilar of Roche\u2019s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we track German physicians\u2019 awareness of\u00a0Truxima and its uptake since its launch to understand how its entry will impact the non-Hodgkin\u2019s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and the increasingly competitive immune biologics market. Along with physicians\u2019\u00a0awareness of, familiarity with, and perceptions of biosimilars in general and of Truxima specifically, we explore the drivers of and barriers to the uptake of biosimilars\/Truxima. We examine promotional efforts, as well as prescriber and nonprescriber profiles, and compare Truxima with other available biosimilars, to better understand the dynamics of the German biosimilars market.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Are German physicians aware of Truxima and its clinical development?<\/li>\n<li>What are the drivers to prescribing Truxima? What is the current level of Truxima use, and how is it changing over time?<\/li>\n<li>Has experience with Truxima changed physicians\u2019 opinions of biosimilars?<\/li>\n<li>Have physicians experienced pressure to prescribe Truxima to patients?<\/li>\n<li>What promotional messages are sales representatives using to sell Truxima and MabThera?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390922","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-geography-germany","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390922\/revisions"}],"predecessor-version":[{"id":394046,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390922\/revisions\/394046"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}